Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression

Area of Science:

• Biotechnology and Nanomedicine
• Cancer Biology and Therapeutics

Background:

• Exosomes are crucial mediators of intercellular communication with therapeutic potential.
• Engineered exosomes (eExosomes) show promise in delivering therapeutic agents to cancer cells.
• A specific need exists for targeted therapies against oral squamous cell carcinoma (OSCC).

Purpose of the Study:

• To develop and evaluate engineered exosomes targeting oral squamous cell carcinoma (OSCC).
• To assess the efficacy of engineered exosomes carrying siRNA against lymphocyte cytoplasmic protein 1 (LCP1) in OSCC.

Main Methods:

• Fibroblast exosomes were engineered to carry Epstein-Barr Virus Induced-3 (EBI3) cDNA and electroporated with siRNA targeting lymphocyte cytoplasmic protein 1 (LCP1) to create octExosomes.
• Loading specificity and effectiveness of siLCP1 within octExosomes were assessed.
• In vitro and in vivo experiments evaluated the anti-oral cancer cell activities of octExosomes.

Main Results:

• Engineered exosomes (octExosomes) demonstrated stability and effective delivery of siLCP1 into OSCC cells.
• LCP1 expression was significantly downregulated in OSCC cells treated with octExosomes.
• OctExosomes exhibited significant tumor-suppressive effects both in vitro and in vivo.

Conclusions:

• Engineered exosomes represent a novel and valuable tool for specifically inhibiting OSCC oncogenic activity.
• The developed octExosomes effectively suppress tumor growth by downregulating LCP1.
• Further investigation into the potential of these engineered exosomes against other human malignant cells is warranted.